HISTORICAL FACTS: 2 - The Untold Story

Canyon launches DT Swiss developed suspension fork with 40mm of travel

The new suspension fork, aimed at gravel riding is the culmination of a 4-year project with DT Swiss

Cycling Weekly · May 27, 2025

Canyon launches new suspension fork and Grail RIFT gravel bike: One is promising but the other feels a little mismatched

The brand's new suspension fork has been designed in partnership with DT Swiss and will feature on a Grail gravel bike

Cycling News · May 27, 2025

5 Momentum Stocks to Buy Now

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of 2025.

Kiplinger · May 21, 2025

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

StockNews.com · Aug 5, 2024

The Canyon Grail CF SLX 8 AXS is one of the best gravel bikes I have ever tested but I would never buy one

Canyon’s Grail is an optimized gravel racing machine, but is it the pinnacle of gravel tech or death by integration?

Bike Perfect · Jul 30, 2024

What You Need to Know Ahead of Illumina's Earnings Release

Illumina is expected to release its second-quarter earnings next month, analysts expect a double-digit earnings dip.

Barchart · Jul 29, 2024

3 Biopharma Stocks to Buy for Long-Term Growth

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

StockNews.com · Jul 15, 2024

3 Biotech Stocks to Monitor for May Moves

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

StockNews.com · May 14, 2024

'You Know You’ve Still Got To Go Through Hell To Get There, But If You Can Get It At Stage 2 or 3'... Hall Of Famer Juli Inkster On New Cancer Screening

Are we entering a new worldwide era for cancer screening?

Golf Monthly · Apr 22, 2024

Illumina Sheds Light, Divests its Cancer Tester, Grail

Illumina, a beacon in genetic science, is set to unfurl its stake in Grail-the stellar creator of cancer-detecting tests–in a dance of corporate divestiture.

Top News · Dec 17, 2023